Have you heard about the Pfizer-Allergan merger? Allergan, the maker of Botox and Juvederm, has merged with Pfizer, the maker of Celebrex. This transaction produces the largest medicines firm in history valued at $160 billion.
More than a hundred novel medicines are in the later stages of development after the merger, making the new company a frontrunner in the field. The positive benefits will reverberate through the medical aesthetics market creating the potential for you as a medical aesthetic practitioner. Medical aestheticians and their patients might expect a revolution in anti-aging care shortly.
As a medical aesthetics practitioner, you need to be prepared to deliver these emerging and new therapies to your patients to help them stay youthful. Someone else will fill the void if you don’t. Keeping up with cutting-edge anti-aging therapies is crucial if you want to be an early adopter and first to market in your area.
The Allergan Pfizer merger is a boon for the field of medical aesthetics.
The future of your success depends on you acquiring cutting-edge anti-aging remedies. New therapies can be expensive, so it’s important to learn how to administer them properly before putting them into practice.
Pfizer-Allergan currently has the range of products necessary to develop new, rapidly expanding pharmaceuticals. The pharmaceutical behemoth has a larger budget for exploring and developing potential treatments for diseases and the effects of aging.
CEO and Chairman of Pfizer, Ian Read, said Read pledged to keep investing heavily in scientific inquiry by pledging $9 billion over the next three years. The goal of pooling these kinds of resources is to end devastating diseases that plague the human race.